Healthcare Industry News: Insulet
News Release - June 8, 2006
Insulet Corporation Names Carsten Boess Chief Financial OfficerBEDFORD, Mass., June 8 (HSMN NewsFeed) -- Carsten Boess, an executive with more than 15 years' experience in corporate finance, has joined Insulet Corporation as Chief Financial Officer. Insulet manufactures the OmniPodŽ Insulin Management System, an innovative new product for the treatment of diabetes that brings together safe, reliable, continuous insulin delivery and blood glucose monitoring in an easy-to-use, two-part system.
As a member of the Insulet executive management team, Boess will be responsible for Insulet's finance and accounting systems as the company expands to full-scale manufacturing of the OmniPod System, as well as for relationships with the company's private investors.
"Carsten Boess' extensive experience as a financial manager in the biotechnology industry and ten years in diabetes therapies complements the experience of our existing management team," said Duane DeSisto, Insulet Corporation President and CEO. "We look forward to his contributions to Insulet as we continue to move the company forward in our mission to improve the lives of people with diabetes."
Prior to joining Insulet, Boess served on the executive management team for Serono, Inc., where he managed 85 employees in the finance, accounting, financial planning and analysis, and investor relations functions. Serono is a global biotechnology company based in Geneva, Switzerland.
Earlier, he was Chief Financial Officer for Alexion Pharmaceuticals, Inc., a publicly-traded biotechnology company based in Cheshire, Conn., where he was responsible for accounting, financial planning and SEC reporting. Boess also served as Vice President of Finance, as a member of the Global Finance Board and in several other finance- and investor relations-related management positions over 10 years with the Novo Group, headquartered in Denmark. In these roles Boess had oversight of nine business areas covering 50 reporting units worldwide.
Carsten Boess, now a resident of Hanover, Mass., earned a B.A. and M.S. in accounting and finance from the University of Odense, Denmark.
About Insulet Corporation
Insulet Corporation, located in Bedford, Massachusetts, is an innovative, privately held, diabetes management company dedicated to designing and developing products that provide superior treatment options and lifelong health benefits for people with diabetes. Insulet Corporation employees have extensive experience in the diabetes and medical device industries. Founded in 2000, the company seeks to improve the lives of people with diabetes -- and to break down the barriers to Continuous Subcutaneous Insulin Infusion (CSII) therapy -- through innovative design and technology, and through feedback from people with diabetes, physicians and diabetes educators. http://www.Insulet.com
Source: Insulet Corp
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.